4-Hydroxytamoxifen(Afimoxifene)

For research use only. Not for use in humans.

目录号:S7827 别名: Afimoxifene 中文名称:4-羟基三苯氧胺

4-Hydroxytamoxifen(Afimoxifene) Chemical Structure

CAS No. 68392-35-8

4-Hydroxytamoxifen (Afimoxifene) 是tamoxifen的活性代谢产物,是一种选择性的雌激素受体调节分子,在乳腺癌的治疗和化学疗法中应用广泛。4-HT可激活intein-Cas9突变体的靶向修饰效率。

规格 价格 库存 购买数量  
RMB 958.6 现货
RMB 4070.46 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的4-Hydroxytamoxifen(Afimoxifene)发表文献5篇:

客户使用该产品的1个实验数据:

  • CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments.

    Oncogene, 2016, 36(16):2255-2264. 4-Hydroxytamoxifen(Afimoxifene) purchased from Selleck.

产品安全说明书

Estrogen/progestogen Receptor抑制剂选择性比较

生物活性

产品描述 4-Hydroxytamoxifen (Afimoxifene) 是tamoxifen的活性代谢产物,是一种选择性的雌激素受体调节分子,在乳腺癌的治疗和化学疗法中应用广泛。4-HT可激活intein-Cas9突变体的靶向修饰效率。
体外研究

4-OHT是有效的ER激活剂,相比于tamoxifen,它对雌激素受体有更高的亲和力。4-OHT具有较强的剂量和时间依赖式效应,能改变分离出来的大鼠心肌细胞的收缩功能[1]。4-HT可激活intein-Cas9突变体的靶向修饰效率[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 cells MW\Qdo9tcW[ncnH0bY9vKGG|c3H5 NYjVVoYyUW6qaXLpeIlwdiCxZjDld5Rzd2enbj3zeIlufWyjdHXkJG1ETi15IHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD1yLkWgcm0> NX34NWN2QTV2OEixOy=>
MCF7 cells MnrZSpVv[3Srb36gZZN{[Xl? MYfJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCPQ1[tO{BjemWjc4SgeJVud3JiY3XscJMhfXOrbnegUWNHNTdiYYPzZZktKEmFNUC9PE42KG6P NYm2XHFMOTJ6MkW5N|U>
MCF7 cells MWjQdo9tcW[ncnH0bY9vKGG|c3H5 MnnxO|IhcA>? MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{IHTldIVv\GWwdDDoeY1idiCPQ1[3JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zMEeg{txO Mo\4NVg5OzVzN{[=
MCF7 cells NELiToFRem:uaX\ldoF1cW:wIHHzd4F6 NUXLW484OjRiaB?= NYXv[ZZySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;OD61JI5O NX6zclVrOTh{N{KyOVY>
T47D:C:4:2 cells MXjGeY5kfGmxbjDhd5NigQ>? NXLk[|lCTXO2cn;n[Y5q[yCjY4Tpeol1gSCjdDD3bYxlKHS7cHWgSXIh[WyyaHGg[ZhxemW|c3XkJIlvKFR2N1S6R|o1QjJiY3XscJMh[2:neIDy[ZN{cW6pIHXzeJJw\2WwIILld5BwdnOnIHXs[Y1mdnRiYomg[JVmdCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYm= M1T2WlIxOzN2M{[4
MDA-MB-231 cells MnnmSpVv[3Srb36gZZN{[Xl? MmK4N{Bl[Xm| NVPkOm5qS3m2b4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IH3pZ5JwfGm2ZYKgZZN{[Xl? M1rJZVIxPTl6NUW1
PC3 cells NGPPeIhRem:uaX\ldoF1cW:wIHHzd4F6 MYe0PEBp MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHHu[JJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCSQ{OgZ4VtdHNiaX7jeYJifGWmIIfpeIghOC54IH7NJI9nKGW|dILh[IlwdCCjbnSgNE44KG6PIH;mJJRme3Sxc4Tldo9v\SCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD15LkW4OVc5KM7:TR?= MnS5NlE2OTN{N{W=
DU145 cells MkDrVJJwdGmoZYLheIlwdiCjc4PhfS=> NH64N5A1QCCq MnH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDhcoRzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iRGWxOFUh[2WubIOgbY5kfWKjdHXkJJdqfGhiMD62JI5OKG:oIHXzeJJi\GmxbDDhcoQhOC55IH7NJI9nKHSnc4Tvd5Rmem:wZTDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2xNE44OTV{IN88US=> MlLBNlE2OTN{N{W=
LNCAP cells M3nFR3Bzd2yrZnXyZZRqd25iYYPzZZk> NUL6eGt5PDhiaB?= NGLOXYJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzJIV5eHKnc4Ppcoch[W6mcn;n[Y4hemWlZYD0c5IhcW6ldXLheIVlKHerdHigNE43KG6PIH;mJIV{fHKjZHnvcEBidmRiMD63JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF05NjNzN{[0JO69VQ>? M1qwNlIyPTF|Mke1
T47D cells M3m5b2N6fG:2b4jpZ4l1gSCjc4PhfS=> NVnUV3I{PSCmYYnz MkXNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC1JIRigXNuIFnDOVA:OC5{MTFOwG0> M{H0XFI{QDZ2OUK4
MDA-MB-231 cells NGn0ZWhRem:uaX\ldoF1cW:wIHHzd4F6 NIPvPWMzPCCq NHvROnFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yOC52IN88US=> MVGyOFE5QTB3NR?=
MCF7 cells NYD6OIZnTnWwY4Tpc44h[XO|YYm= MXqxNEDPxE1? MXe2JIg> NEn1WZJWeHKnZ4XsZZRqd25ib3[gSXJidHCqYTDwdo91\WmwIHzleoVteyCrbjDoeY1idiCPQ1[3JINmdGy|IHH0JFExKHWPIHHmeIVzKDZiaILzJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R? NFraXVQzPDN|Mk[zNC=>
SKOV3 cells M3Xab2Z2dmO2aX;uJIF{e2G7 M3vTSlQ5KGh? MnLLRY51cWOjbnPldkBi\2GrboP0JIh2dWGwIGPLU3Y{KGOnbHzzJI93\XKneIDy[ZN{cW6pIGCt[5Ah[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME23MlQ3KM7:TR?= NHftOWwzPDl2NkG0OS=>
MDA-MB-231 cells NIny[YdHfW6ldHnvckBie3OjeR?= Ml3JOFghcA>? NXTHblI5SW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME21MlQh|ryP M2XCWFI1QTR4MUS1
MCF7 cells NFvWVGtHfW6ldHnvckBie3OjeR?= NGj2SVM1QCCq M1[2VWFvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDFVk1xd3OrdHn2[UBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9PU4zKM7:TR?= MoD0NlQ6PDZzNEW=
MDA-MB-231 cells MUjGeY5kfGmxbjDhd5NigQ>? MV20PEBp NV[3e4JzSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNW6nZ3H0bZZmKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME22MlIh|ryP Mme0NlQ6PDZzNEW=
MCF7 cells MoT4SpVv[3Srb36gZZN{[Xl? MnLhNlUxKHSxIEWwNEBvVQ>? MX[1JIRigXN? MorURY51cWOjbnPldkBi\2GrboP0JIh2dWGwIFXSMZBwe2m2aY\lJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBme3S{YXTpc4wucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44h[XRiMkWwJJRwKDVyMDDuUUBi\nSncjC1JIRigXN? MVWyOFk1PjF2NR?=
MCF7 cells NF:2[Y1EgXSxdH;4bYNqfHliYYPzZZk> NYLUeXE2PDhiaB?= NFvyOIREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVMvPiEQvF2= M2PDdFI2PjF6NUm1
DU145 cells MY\Qdo9tcW[ncnH0bY9vKGG|c3H5 NYLub4RMPzJiaB?= NVzOZo9GSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OTVwMzFOwG0> MmDLNlU6QTN{Nkm=
african green monkey Vero cells NEfh[YRRem:uaX\ldoF1cW:wIHHzd4F6 NUPzUo1YPzJiaB?= NW\0V2hsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBi\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xOU4yKM7:TR?= NHrRNpUzPTl7M{K2PS=>
BT-20 cells M37LZXBzd2yrZnXyZZRqd25iYYPzZZk> NH\Ifm5KdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QheHKxbHnm[ZJifGmxbjDv[kBDXC1{MDDj[YxteyCrbjDwdoV{\W6lZTDv[kBVWEViYYSgNVBmNTViTTDjc45k\W62cnH0bY9v NYq2fVR3Ojd4OU[4NS=>
Ishikawa endometrial cells NF\yXpRHfW6ldHnvckBie3OjeR?= MmLORY51[WexbnnzeEBi[3Srdnn0fUBieyCrbnjpZol1cW:wIH;mJFEhdk1iMUetZoV1[S2nc4TyZYRqd2xic4TpcZVt[XSnZDDhcItidGmwZTDwbI9{eGijdHHz[UBqdmS3Y4Tpc44hcW5iSYPobYtif2FiZX7kc41mfHKrYXygZ4VtdHNuIFnDOVA:OC53MTFOwG0> NHrYeYYyPTN6MEKwPC=>
MCF-7-2a cells MoK3SpVv[3Srb36gZZN{[Xl? MkLLTY5pcWKrdHnvckBw\iCnc4TyZYRqd2xiaX7keYNm\CCnc4Tyc4dmdiC{ZXPldJRweiC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCrbjDNR2YuPy1{YTDj[YxteyxiSVO1NF0xNjByNzFOwG0> Mn3KNVI3PzJ{NEm=
Calu-1 cells M3WwUWZ2dmO2aX;uJIF{e2G7 MlfLN|AhdWmwcx?= NIfUVWJKdmirYnn0bY9vKG:oIGDMSFEhcW5iaIXtZY4hS2GudT2xJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHCqb4PwbIF1cWS7bHL1eIFvd2xvW3S5YUBxem:mdXP0bY9vKGGodHXyJFMxKG2rboOgZpkhdWG|czDzdIVkfHKxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVQvQCEQvF2= NV64cm8zOTlzM{[5O|U>
MCF12A cells NUPocXdOWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUi0PEBp NWSzdoJ7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUWNHOTKDIHPlcIx{KGmwY4XiZZRm\CC5aYToJFAvODB|IH7NJI9nKGW|dILh[IlwdCCjbnSgNE4xOSCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYmgbY4heHKnc3XuZ4Uhd2ZiNTWg[oV1[WxiYn;2bY5mKHOncoXtMEBIUTVyPUOuN|EyOzFizszN MorPNlE2OTN{N{W=
MCF7:WS8 cells NIf5fnBHfW6ldHnvckBie3OjeR?= NGC0[lVC[3SrdnH0bY9vKG:oIHj1cYFvKEWUIHnuJIh2dWGwIF3DSlc7X1N6IHPlcIx{KGW6cILld5NqdmdiZYP0do9o\W5icnXzdI9ve2m4ZTDlcIVu\W62IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? MkHLNlA{OzR|Nki=
HEK293 cell MmXjSpVv[3Srb36gZZN{[Xl? MkDjN|AhdWmwcx?= M{\KS2lvcGmkaYTpc44hd2ZiR1\QMZRi\2enZDDoeY1idiCSTFSyJIV5eHKnc4Pl[EBqdiCqdX3hckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heGixc4DoZZRq\HmuYoX0ZY5wdC2dZEndJJBzd2S3Y4Tpc44h[W[2ZYKgN|AhdWmwczDifUBu[XO|IIPw[YN1em:vZYTybYMh[W6jbInzbZMtKEmFNUC9NE4xPDRizszN MlG1NVkyOzZ7N{W=
MCF12A cells NXnubHBFWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mn35OFghcA>? NYfnVnRJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUWNHOTKDIHPlcIx{KGmwY4XiZZRm\CC5aYToJFAvODZibl2gc4Yh\XO2cnHkbY9tKGGwZDCwMlA4KG6PIH;mJJRme3Sxc4Tldo9v\SCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTDpckBxemW|ZX7j[UBw\iCoZYThcEBjd3[rbnWgd4VzfW1iYX7kJG52W2W{dX2sJGdKPTB;Mz64PVA1PSEQvF2= MoPqNlE2OTN{N{W=
HEK293 cells NUHkdFlYTnWwY4Tpc44h[XO|YYm= NYnYZ3JFSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBme3S{b3flckBz\WyjdHXkJJJm[2WydH;yJIdidW2jIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCJSUWwQVEvOzVizszN Mm\KNlU{ODV4OEi=
rat GH3 cells MWHGeY5kfGmxbjDhd5NigQ>? Mlf0OFghcA>? M3ziTWFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTZiTTDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{ M1L5dlI1QDB3MUm5
MCF7:WS8 cells NUjUbnAxTnWwY4Tpc44h[XO|YYm= NUOyO5BnPDhiaB?= MorORYdwdmm|dDDhZ5Rqfmm2eTDheEBGWiCrbjDoeY1idiCPQ1[3PndUQCClZXzsd{Bie3Onc4Pl[EBieyCJUlXCNUBo\W6nIHX4dJJme3Orb36gZZQhOTBpLU[gUUBi\nSncjC0PEBpenNiYomgVnQuWEOUIHHuZYx6e2m| NHGycVczPDhyNUG5PS=>
rat GH3 cells M1;xdGZ2dmO2aX;uJIF{e2G7 NVnTT2E6PDhiaB?= M2ewXWFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTFyIITvJFExLy14IF2gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>? MmDMNlQ5ODVzOUm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK / p-MEK / MEK1 / MEK2 / p21 / Cyclin D1 ; 

PubMed: 26163823     


LNCaP-Raf:ER cells were treated with increasing doses of 4-hydroxytamoxifen for 2 days. The bottom panel indicates densitometry of MEK1 and MEK2 signals. Data (mean ± standard error) are from two independent experiments. Pearson’s r = 0.823 for MEK1 and −0.673 for MEK2. 

26163823
Growth inhibition assay
Cell viability; 

PubMed: 26014809     


Dose-dependent effect of 4-hydroxytamoxifen on survival of T47D, MCF-7 and BT-474 cell lines after 96 h of treatment. Control samples were treated with appropriate concentrations of DMSO. Viability was assayed by MTT method.

26014809

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: 成年大鼠和小鼠心肌细胞
  • Concentrations: 0, 0.5, 1, 3, 5, and 10 礛
  • Incubation Time: 15-45 min
  • Method:

    细胞置于含有4OHT的台式液中,孵育温度为36 ± 1°C,以0.2Hz的频率予以刺激,测量其肌节长度。


    (Only for Reference)
动物实验:

[2]

- 合并
  • Animal Models: SD大鼠(Sprague-Dawley rats)
  • Dosages: 21 mg/kg, 54 μmol/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 77 mg/mL (198.7 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 387.51
化学式

C26H29NO2

CAS号 68392-35-8
储存条件 粉状
溶于溶剂
别名 Afimoxifene

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03199963 Terminated Drug: 4-OH tamoxifen|Drug: Placebo Mammographic Breast Density BHR Pharma LLC August 21 2017 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Estrogen/progestogen Receptor Signaling Pathway Map

相关Estrogen/progestogen Receptor产品

Tags: 购买4-Hydroxytamoxifen(Afimoxifene) | 4-Hydroxytamoxifen(Afimoxifene)供应商 | 采购4-Hydroxytamoxifen(Afimoxifene) | 4-Hydroxytamoxifen(Afimoxifene)价格 | 4-Hydroxytamoxifen(Afimoxifene)生产 | 订购4-Hydroxytamoxifen(Afimoxifene) | 4-Hydroxytamoxifen(Afimoxifene)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID